Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/181799
Title: Clinical effectiveness and bacteriological eradication of three different Short-COurse antibiotic regimens and single-dose fosfomycin for uncomplicated lower Urinary Tract infections in adult women (SCOUT study): study protocol for a randomised clinical trial
Author: Garcia Sangenís, Ana
Morros Pedrós, Rosa
Aguilar Sánchez, Mercedes
Medina Perucha, Laura
Leiva, Alfonso
Ripoll, Joana
Martínez Pecharromán, Mar
Bartolomé Moreno, Cruz B
Magallon Botaya, Rosa
Marín Cañada, Jaime
Molero, José M.
Moragas, Ana
Troncoso, Amelia
Monfà, Ramon
Llor, Carl
Keywords: Infeccions del tracte urinari
Terapèutica
Antibiòtics
Urinary tract infections
Therapeutics
Antibiotics
Issue Date: 1-Nov-2021
Publisher: BMJ
Abstract: Introduction: Uncomplicated lower urinary tract infections (uLUTI) are a common problem in primary care. Current local guidelines recommend the use of a single 3 g dose of fosfomycin. However, most general practitioners (GP) prefer short-course therapies to single-dose therapy. No study has compared head-to-head short-course antimicrobial agents for uLUTIs. Therefore, the aim of this randomised clinical trial is to compare three different short-course antibiotic therapies with a single-dose of fosfomycin for these infections. Methods and analysis: This will be a pragmatic, multicentre, parallel group, open trial. Women aged 18 or older and with symptoms of uLUTI and a positive urine dipstick analysis will be randomised to one of the following four groups: a single dose of 3 g of fosfomycin, 2 days of 3 g of fosfomycin o.d., 3 days of pivmecillinam 400 mg three times per day (t.i.d) or 5 days of nitrofurantoin 100 mg t.i.d. A total sample of 1120 patients was calculated. The primary endpoint is clinical effectiveness at day 7, defined as cure of symptoms reported by the patients in a diary including four symptoms: dysuria, urgency, frequency and suprapubic pain, which will be scored on a 4-point severity scale (not present/mild/moderate/severe). Follow-up visits are scheduled at days 7 (phone call), 14 and 28 for assessing evolution. Urine samples will be collected in the three on-site visits and urine cultures performed. If positive, antibiograms for the three antibiotics studied will be performed. Bacterial eradication will be measured at days 14 and 28.
Note: Reproducció del document publicat a: https://doi.org/10.1136/bmjopen-2021-055898
It is part of: BMJ Open, 2021, vol. 11, num. 11
URI: http://hdl.handle.net/2445/181799
Related resource: https://doi.org/10.1136/bmjopen-2021-055898
ISSN: 2044-6055
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
e055898.full.pdf581.89 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons